Parkinson's Archives - Purablis-Medicinal Tinctures with CBD, THCA and THC

Parkinson’s Marijuana Studies and

Parkinson’s Cannabis Research

09/28/2018

Author(s): Marcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, Márcio Alexandre Pena-Pereira, Emmanuelle T Sobreira, Mateus M Bergamaschi, Antonio Carlos dos Santos, Antonio Lucio Teixeira, Jaime EC Hallak and José Alexandre S Crippa.

CBD has a promising use to improve the quality of life of patients with Parkinson’s disease without psychiatric comorbidities. View study

09/28/2018

Author(s): Sandeep Vasant More and Dong-Kug Choi*.

The use of cannabinoids as a new therapeutic target has been recommended as a promising therapy for Parkinson’s disease, as the growing evidence suggests a prominent modulating function of the cannabinoid signaling system in the basal ganglia. View study

09/28/2018

Author(s): Katerˇina Venderova´, PharmD, PhD, Evzˇen Ru˚zˇicˇka, MD, DSc, Viktor Vorˇı´sˇek, PharmD, and Peter Visˇnˇovsky´, MD, PhD.

Interesting questionnaires that show that bradykinesia seems to be the symptom most commonly improved by cannabinoids, followed by muscle rigidity and tremor. In addition, the use of cannabis causes the relief of dyskinesias induced by dopaminergics. View study

09/28/2018

Author(s): Marta Celorrio a, b, Estefanía Rojo-Bustamante a, b, Diana Fernandez-Su  arez  a, Elena Saez  c, Ander Estella-Hermoso de Mendoza c, Christa E. Müller d, María J. Ramírez e, g, Julen Oyarzabal  c, Rafael Franco a, f, María S. Aymerich.

For the first time it is demonstrated that the activation of the GPR55 receptor by. View study

09/28/2018

Author(s): M. H. N. Chagas MD PhD, A. L. Eckeli MD PhD, A. W. Zuardi MD PhD, M. A. Pena-Pereira MD, M. A. Sobreira-Neto MD, E. T. Sobreira PhD, M. R. Camilo MD, M. M. Bergamaschi PhD, C. H. Schenck MD, J. E. C. Hallak MD PhD, V. Tumas MD PhD and J. A. S. Crippa MD PhD.

A synthetic cannabidiol isomer (CBD) may be beneficial in combating Parkinson’s disease. View study

09/28/2018

Author(s): Lu Song Xinxin Yang Yaping Ma Na Wu Zhenguo Liu.

The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used effectively to treat Parkinson’s disease. However, its long-term administration produces serious complications. In this study, the active participation of CB1 receptors in the regulation of the action of L-DOPA during the treatment of Parkinson’s Disease is evidenced. View study

09/28/2018

Author(s): S G Fagan and V A Campbell.

Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study